3 Stocks Pushing The Health Services Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 52 points (0.3%) at 17,129 as of Tuesday, Aug. 26, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,998 issues advancing vs. 975 declining with 164 unchanged.

The Health Services industry currently sits up 0.3% versus the S&P 500, which is up 0.2%. Top gainers within the industry include ResMed ( RMD), up 1.4%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 0.9%, Humana ( HUM), up 0.7%, Abbott Laboratories ( ABT), up 0.7% and HCA Holdings ( HCA), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Grifols ( GRFS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.35 (-0.9%) to $39.19 on average volume. Thus far, 402,190 shares of Grifols exchanged hands as compared to its average daily volume of 727,000 shares. The stock has ranged in price between $39.15-$39.71 after having opened the day at $39.50 as compared to the previous trading day's close of $39.54.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $13.4 billion and is part of the health care sector. Shares are up 7.6% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Grifols Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Quest Diagnostics ( DGX) is down $0.63 (-1.0%) to $62.11 on light volume. Thus far, 221,377 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $62.09-$62.81 after having opened the day at $62.78 as compared to the previous trading day's close of $62.74.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $9.0 billion and is part of the health care sector. Shares are up 17.2% year-to-date as of the close of trading on Monday. Currently there are 2 analysts that rate Quest Diagnostics a buy, 3 analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.83 (-0.7%) to $120.97 on light volume. Thus far, 402,212 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $120.93-$122.02 after having opened the day at $121.96 as compared to the previous trading day's close of $121.80.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. Thermo Fisher Scientific has a market cap of $48.4 billion and is part of the health care sector. Shares are up 9.4% year-to-date as of the close of trading on Monday. Currently there are 13 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Thermo Fisher Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing